Monitor for FDA safe-to-proceed feedback on TBS-2025 IND and initiation of Phase 1b/2 trial in 2H 2026, which could be a catalyst. Cash runway into 2028 reduces near-term financing risk, but increasing burn rate and reliance on credit facility warrant caution. No EPS or revenue data to drive sentiment.
Price Chart
Executive Summary
TuHURA Biosciences reported Q2 2026 financial results with no revenue or EPS, as the company remains pre-revenue. Cash stood at $1.0M at June 30, 2026, with $5.7M drawn from a $50M credit facility, extending runway into 2028. R&D expenses rose to $6.6M (vs $4.9M a year ago) and operating cash outflow widened to $13.0M in H1 2026, reflecting increased clinical activity. The filing is a routine quarterly update with no material financial surprises.
Key Facts
- Cash and cash equivalents of $1.0M at June 30, 2026
- $5.7M drawn to date from $50M credit facility (including $2.15M post-quarter)
- R&D expenses $6.6M in Q2 2026 vs $4.9M in Q2 2025
- Net cash outflow from operations $13.0M in H1 2026 vs $10.9M in H1 2025
- Common shares outstanding ~63.7M at June 30, 2026
- Pipeline milestones: IFx-2.0 Phase 3 enrollment target 2H 2027; TBS-2025 IND filed; MDSC inhibitor POC studies expected 2H 2026
Financial Impact
No revenue or EPS reported; cash burn increasing with operating cash outflow of $13.0M in H1 2026; credit facility provides runway into 2028 but dilution risk from ATM program ($0.4M raised in April/July 2026)
Risk Factors
- Dilution risk from ATM program and potential future equity offerings
- Clinical trial execution risk for IFx-2.0 Phase 3 and TBS-2025 Phase 1b/2
- Cash burn rate increasing; may require additional financing beyond credit facility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851514 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $1.78 | awaiting T+60 | — | $2.04 (+14.61%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.04 (−2.86%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.04 (−2.86%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.04 (−2.39%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.04 (−3.77%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.04 (−8.11%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.04 (−17.41%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.04 (−17.41%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.04 (−17.41%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.04 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers